English  |  正體中文  |  简体中文  |  Items with full text/Total items : 43312/67235
Visitors : 2137384      Online Users : 2
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU/NCHU Library IR team.
National Chung Hsing University Institutional Repository - NCHUIR > 生命科學院 > 基因體暨生物資訊學研究所 > 依資料類型分類 > 期刊論文 >  Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients without Previous Tyrosine Kinase Inhibitor Treatment

Please use this identifier to cite or link to this item: http://nchuir.lib.nchu.edu.tw/handle/309270000/133544

標題: Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients without Previous Tyrosine Kinase Inhibitor Treatment
作者: Chen, Y.T.;Chang, J.W.C.;Liu, H.P.;Yu, T.F.;Chiu, Y.T.;Hsieh, J.J.;Chen, Y.R.;Wu, H.D.I.;Huang, S.F.
陳盈璁
關鍵字: MET amplification;EGFR;NSCLC;Tyrosine kinase inhibitor;Chemotherapy;Gene dosage;growth-factor receptor;in-situ hybridization;c-met;copy number;juxtamembrane domain;somatic mutations;amplification;gefitinib;adenocarcinoma;carcinomas
日期: 2011
Issue Date: 2012-12-14 10:01:04 (UTC+8)
關連: Journal of Thoracic Oncology, Volume 6, Issue 12, Page(s) 2027-2035.
摘要: Introduction: Recently, two studies revealed that MET amplification was associated with secondary epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients. But it remains uncertain whether MET amplification could be related to primary TKI resistance in NSCLC because of limited data. Materials and Methods: MET gene dosage of the tumor tissues from 208 NSCLC patients was investigated by real time quantitative polymerase chain reaction and compared with molecular and clinical features, including EGFR mutations, KRAS mutations, EGFR gene copy numbers, and patient survivals. Three copies were used as the cutoff. Among them, 25 patients were also evaluable for EGFR TKI responsiveness. Results: The proportion of high MET gene dosage was 10.58% (22/208) with higher incidence in squamous cell carcinoma (11.86%) and smokers (16.18%), although the differences with adenocarcinoma and nonsmokers were nonsignificant. Coexisting EGFR mutations were identified, and the incidence (8.54%) was similar to wild type (12.0%). High MET gene dosage was significantly associated with higher tumor stage (stage I + II versus stage III + IV; p = 0.0254) and prior chemotherapy for stage III + IV adenocarcinoma patients (35.71% versus 7.41%; p = 0.0145) but not correlated with primary TKI resistance. Among the 155 surgically resectable patients (stage I to IIIA), high MET gene dosage was significantly associated with shorter median survival (21.0 months versus 47.1 months; p = 0.042) by univariate analysis. Conclusions: High MET gene dosage was not related to primary TKI resistance and the incidence was increased after chemotherapy, suggesting high MET gene dosage may also be related to chemotherapy resistance.
Relation: Journal of Thoracic Oncology
Appears in Collections:[依資料類型分類] 期刊論文
[依教師分類] 陳盈璁
[依教師分類] 陳盈璁

loading Web of Knowledge data....

Files in This Item:

File SizeFormat
index.html0KbHTML376View/Open


 


學術資源

著作權聲明

本網站為收錄中興大學學術著作及學術產出,已積極向著作權人取得全文授權,並盡力防止侵害著作權人之權益。如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員,將盡速為您處理。

本網站之數位內容為國立中興大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用。

聯絡網站維護人員:wyhuang@nchu.edu.tw,04-22840290 # 412。

DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU/NCHU Library IR team Copyright ©   - Feedback